Madiha Derouazi

CEO of Amal Therapeutics

Madiha Derouazi has been working on vector engineering and therapeutic cancer vaccines for over 10 years.  She has a strong background in applied molecular and cellular biotechnology, with research interests at the interface of fundamental and translational research. After several years working on recombinant protein production (upstream), she started developing different antigen delivery vectors. In the Laboratory of Tumor Immunology of the University of Geneva, she designed and characterized the CPP-based multi-epitopic cancer vaccine that is currently being progressed by Amal Therapeutics. Madiha Derouazi holds a PhD in Biotechnology from the Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland and a Master in Biotechnology Engineering from the University of Technology of Berlin, Germany.

Our Sponsors